Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Suppression of HAMA and HATA to LMB-1 in Advanced Carcinoma
NCT00001805Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 1999
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2 trial of rituximab in solid tumor, sponsored by National Cancer Institute. Primary endpoint: Human Antimouse Antibody and Human Antitoxin Antibody response. Started Mar 1999; status: completed.
02
Drugs
rituximab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT00001805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001805.